EYPT
Eyepoint Pharmaceuticals Inc
3.70$
-8.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 7.9% | 7.1% | 6.5% | 14.8% | 7.0% | 7.0% | 3.3% | 3.1% | 74.6% | 60.5% | 75.9% | 0.0% | 58.2% | |
| 92.1% | 92.9% | 93.5% | 85.2% | 93.0% | 93.0% | 96.7% | 96.9% | 25.4% | 39.5% | 24.1% | 100.0% | 41.8% | |
| 114.2% | 128.0% | 258.0% | 314.7% | 280.7% | 374.3% | 239.5% | 1,040.7% | 4,943.5% | 9,550.6% | 10,366.1% | 16,491.9% | 9,420.2% | |
| 69.4% | 80.2% | 120.7% | 134.5% | 123.2% | 108.6% | 56.7% | 222.4% | 1,500.0% | 1,835.8% | 2,190.1% | 2,809.1% | 1,984.8% | |
| 186.8% | 209.5% | 378.7% | 449.7% | 404.2% | 483.4% | 296.4% | 1,263.7% | 6,446.2% | 11,385.5% | 12,556.6% | 19,307.1% | 11,407.0% | |
| -94.7% | -116.6% | -285.2% | -364.5% | -311.2% | -390.4% | -199.7% | -1,166.8% | -6,420.8% | -11,346.0% | -12,532.5% | -19,207.1% | -11,365.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | – | – | – | – | – | – | – | |
| -83.0% | -99.9% | -250.6% | -325.3% | -279.0% | -356.5% | -184.8% | -1,112.6% | -6,183.4% | -10,874.7% | -12,195.7% | -18,633.1% | -10,989.9% | |
| 12.0% | 0.6% | 0.0% | – | – | 0.8% | – | 1.7% | – | -30.0% | 7.2% | – | – | |
| -83.0% | -100.5% | -250.6% | -325.3% | -279.0% | -357.3% | -184.8% | -1,114.3% | -6,183.4% | -10,904.7% | -12,188.5% | -18,633.1% | -10,994.7% | |
| -82.2% | -99.1% | -248.0% | -321.5% | -275.1% | -352.3% | -182.8% | -1,102.5% | -6,123.8% | -9,332.7% | -12,104.3% | -18,371.6% | -10,556.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.